期刊文献+

力尔凡对晚期非小细胞肺癌化疗的影响 被引量:6

Effect of LIFEIN in Treatment of Advanced Non-Small Cell Lung Cell Cancer
下载PDF
导出
摘要 比较全身化疗加或不加力尔凡对晚期非小细胞肺癌(NSCLC)的疗效、不良反应及免疫功能的变化。方法:将60例晚期NSCLC患者以随机方法(开信封)分别分为并用力尔凡组(治疗组)和单用化疗组(对照组),分别接受NP方案(诺维苯、顺铂)加力尔凡或单用NP方案化疗。结果:1)治疗组部分缓解率43.3%,对照组33.3%(P>0.05),中位缓解期分别为4.8个月及3.3个月。2)治疗组疗后和疗前相比CD4及CD4/CD8值显著升高(P<0.05),而对照组则相反,两组差异显著(P<0.05)。3)不良反应:治疗组白细胞下降63.3%,对照组达100%(P<0.05)。结论:力尔凡与化疗同时应用治疗晚期NSCLC,疗效有所提高,可增强细胞的免疫功能,对化疗引起的白细胞下降有保护作用。 Objective:To compare the response rate,toxicity and immunological effect of NP regimen with or without LIFEIN for advanced non-small cell lung cancer(NSCLC).Methods:Sixty patients with advanced NSCLC were randomly divided into treatment group and control group re ceiving NP regimen(Navelbine,cisplatin)plus LIFEIN or NP regimen alone respectively.Results:1)The partial response rate was43.3%in treatment group and33.3%in control group(P>0.05).The median response duration was4.8months and3.3months in these tow groups re-spectively.The mean survival time was9.6months in the treatment group and8.5months in the control group.2)the levels of CD4and CD4/CD8were significantly increased in the treatment group whereas no change in the control group(P<0.05).3)Toxicity:19patients of30(63.3%)in treatment group who underwent Lecucocyte count reduction,which was observed in all the pa-tients(100%)in control group.Conclusion:LIFEIN has some functions of potentiating the antitu-mor effect of chemotherapy,enhancing the immunofunctions of the patients treated with chemotherapy,reversing the decreasing of leucocyte count induced by chemotherapy,and the toler-ance is well.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2003年第4期286-287,292,共3页 Chinese Journal of Clinical Oncology
关键词 晚期 非小细胞肺癌 力尔凡 化疗 Advanced non-small cell cancer LIFEIN Chemotherapy
  • 相关文献

参考文献16

二级参考文献36

共引文献713

同被引文献67

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部